anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
A kind of pure Chinese medicine disinfectant disclosed by the invention and its equipment, are prepared by following steps：A. raw material prepares；B. it impregnates；C. boiling and initial concentration；D. final concentration；E. match liquid.A kind of pure Chinese medicine disinfectant of the present invention is acted synergistically by drug matching, germ can quickly be killed, killed the virus, acting on 35 minutes can make germ or virus be killed or be inactivated, it is quick, without side-effects, and skin can be in direct contact, cross-infection and the propagation of germ virus are avoided, it is non-corrosive to medical instrument, furniture, leather, plastics, tableware, it is also pollution-free to environment.Its advantage is in terms of existing technologies：Preparation process is simple and convenient to operate, and hepatitis A virus and hepatitis B, which are acted on 5 minutes 100%, has complete inactivation effect, and can eliminate AIDS virus antigen.
BACKGROUND: A straight silicone stent can be used to treat proximal benign tracheal stenosis in non-surgical candidates. However, stent migration is a common complication when placed at a particular location and can lead to major complications. This case series of laryngotracheal stenosis reports a fixation method for straight silicone stents in the subglottic trachea (Stage 3 of the McCaffrey classification).
METHODS: The medical charts of these patients scheduled for straight silicone stent placement with suture fixation between 2014 and 2020 at the CHU UCL Namur Hospital (Belgium) were retrospectively reviewed. The procedure was performed using a rigid bronchoscope. Details of the procedure were obtained from medical records.
RESULTS: This case series included six patients (males: 4, females: 2). The median patient age was 59 years. Two suture fixations were placed following previous silicone stent migration episodes, whereas the others were placed proactively to avoid this risk. All fixations were performed by the device Freka® Pexact II ENFIt®, originally developed for gastropexy in endoscopic gastrostomy. The sutures were subcutaneously buried.
CONCLUSIONS: During the 6-month follow-up period, complications such as fixation issues and stent migration were reported despite the off-label use of the treatment. The straight silicone stent fixation technique used in this case series was simple and effective for securing the stent in upper benign tracheal stenosis.
The present invention relates to a method of selecting (a) cell(s), (a) tissue(s) or (a) cell culture(s) with susceptibility to an HSP90 inhibitor. Also a method for determining the responsiveness of a mammalian tumor cell or cancer cell to treatment with an HSP90 in-hibitor is described herein. In particular, the present invention provides for an in vitro method for the identification of a responder for or a patient sensitive to an HSP90 inhibitor and uses of an oligo- or polynucleotide capable of detecting (an) activating mutation(s) in the KRAS gene are provided. The present invention also relates to a method of monitoring the efficacy of a treatment of a cancer characterized by the presence of at least one activating mutation in the KRAS gene, and. optionally, in the EGFR  gene and/or the BRAF gene. In addition, a method of predicting the efficacy of a cancer treatment is described, in particular in a cancer that is characterized by the presence of at least one activating mutation in the KRAS gene. and.  optionally, in the EGFR gene and/or the BRAF  gene. Also the use of a(transgenic) non-human animal or a(transgenic) cell having at least one activating mutation in the KRAS gene, and, optionally, in the EGFR gene and/or the BRAF gene for screening and/or validation of a medicament for the treatment of said cancer is described and a kit useful for carrying out the methods described herein is provided.
Unmet need ATC is a very serious condition and is, apart from a few exclusive cases, always lethal. Many patients suffer uncontrollable loco-regional disease with even so uncontrollable complaints of airway obstruction, oesophagus obstruction, pain and neck movement impairment. One of the only shown beneficial treatment is complete surgical resection with clear surgical margins combined with radiotherapy and systemic treatment. However, in less than 10-15% of the patients the pathologist reports clear surgical margins. Thereby it is noticeable that surgery often results in serious morbidity, due to an esophagectomy, laryngectomy or trachea resection all accompanied by an extensive reconstruction. All of these come with serious morbidity and seldomly lead to clear margins and better outcome.

Proposed solution A single center, phase II study for the evaluation of safety and efficacy of neo-adjuvant and adjuvant dabrafenib/trametinib treatment in BRAF mutated ATC patients. By introducing neo-adjuvant treatment the hypothesis is that better selection is done for patients who are eligible for complete surgery and that surgery results more often in clear surgical margins after neo-adjuvant treatment. Second benefit of treating patients with combined loco-regional and systemic agents before surgery is that micro/macrometastases (being there in at least 30% of the patients at diagnosis) are already being treated directly after diagnosis. Lastly, adjuvant treatment with dabrafenib/trametinib will hopefully result in reduction of local and distant recurrences after surgery.
BL-7040 is an orally available new chemical entity for the treatment of IBD. BL-7040 is a synthetic oligonucleotide with dual activity on both the nervous and immune systems.
antibodies specific for the major protein of royal jelly can be used in a method for purifying the major protein of royal jelly including the major protein of natural royal jelly. These methods can produce compositions enriched in the major proteins of natural royal jelly. The purified royal jelly major protein can be used to produce a cosmetic product comprising a natural royal jelly major protein. Antibodies specific for the major protein of royal jelly can be used in a method for purifying the major protein of royal jelly including the major protein of natural royal jelly. These methods can produce compositions enriched in the major proteins of natural royal jelly. The purified royal jelly major protein can be used to produce a cosmetic product comprising a natural royal jelly major protein. The isolated nucleic acid encodes a monoclonal antibody that specifically binds to a major protein of royal jelly.
For 12000 patients regardless of cancer diagnosis or polypectomy, if there is polyp, NBI (magnification) observation is required, with 4 white light and NBI images collected and reserved, respectively. If there is magnifying endoscopy, another 4 endoscopic images of magnification are also required. Endoscopists are invited to predict the pathology of polyps according to the NICE classification principle and endoscopic images, and upload the pathological results and endoscopic images within 2-4 week after colonoscopy.
The investigators anticipate to undertaking a prospective, multicenter, randomised controlled trial of 60 ITP adult patients. One part of the participants are randomly selected to receive vitamin D (given Rocaltrol orally at a dose of 0.25 μg per day for 1 month), combining with dexamethasone (given orally at a dose of 40 mg per day for 4 days, two-cycles with an interval of 10 days); the others are selected to receive high-dose of dexamethasone treatment plus placebo. Platelet count, bleeding and other symptoms were evaluated before and after treatment. Serum calcium and creatinine are monitored. Adverse events are also recorded throughout the study. In order to report the efficacy and safety of vitamin D combining with high-dose dexamethasone therapy for the treatment of adults with ITP.
FIELD: medicine, pharmacy. SUBSTANCE: invention relates to agents eliciting an antibacterial effect. Composition is made as a capsule. Composition comprises, g per 1 capsule: azithromycin dihydrate, 0.2682; calcium stearate, 0.0080; maize starch, 0.04; microcrystalline cellulose, 0.0338. This ratio of components is optimal and provides the necessary quality of composition. Invention can be used for treatment of upper and lower respiratory ways, urinary way, skin infections and soft tissues. EFFECT: expanded assortment of antibacterial preparations, valuable medicinal properties of composition. 1 dwg, 5 tbl
PURPOSE:To obtain a composition for oral cavity application, exhibiting excellent effect for suppressing the proliferation of oral bacteria by synergistic action and useful for the prevention of foul breath by using a chlorhexidine salt in combination with a glucose fatty acid ester. CONSTITUTION:A chlorhexidine salt is compounded in combination with a glucose fatty acid ester of formula (R is 8-14C saturated or unsaturated fatty acid residue). The compound of formula is e.g. glucose monocaprylate, glucose monocaprate and glucose monolaurate. The amount of the compound of formula in the composition is usually 0.1-10%, especially 0.5-5%. Other surfactant may be compounded to the above composition to an extent not to deteriorate the effect of the compound of formula.
The role of aspirin in cardiovascular primary prevention remains controversial. There are physiological reasons to explore its potential benefits in patients with high levels of lipoprotein(a) [Lp(a)], mainly due to its antifibrinolytic properties and interactions with platelets. The primary objective of this systematic review was to evaluate the cardiovascular benefits and bleeding risks associated with aspirin use in patients who have elevated Lp(a) levels but no history of cardiovascular disease. This systematic review was conducted following PRISMA guidelines. We performed a literature search to identify studies assessing the cardiovascular benefits and bleeding risks of aspirin use in patients with elevated Lp(a) levels (or a related genetic variant) who have no history of cardiovascular disease. Five studies (49,871 individuals) were considered for this systematic review. Three studies assessed the impact of aspirin use in relation to genetic variants associated with elevated Lp(a) levels (SNP rs379822), while the remaining two studies directly measured plasma levels of Lp(a). The endpoints evaluated varied among the studies. Overall, the findings consistently show that carriers of the apolipoprotein(a) variant or patients with Lp(a) levels > 50 mg/dL experience a reduction in cardiovascular risk with aspirin use. No significant bleeding issues were observed, although such events were reported in only two studies. This systematic review suggests that aspirin use in patients with elevated Lp(a) levels and no prior cardiovascular history may reduce cardiovascular risk. The available data on bleeding risk is insufficient.
PURPOSE: Method, apparatus, ultrasonic diagnosis apparatus and medical imaging system are provided to increase accuracy of readout by generating and displaying an ultrasonic standard image. CONSTITUTION: An image data acquisition unit(110) acquires ultrasonic image data. The ultrasonic image data display information about a target subject. A standard image generation unit(120) is based on a reference image about at least one standard plane. The standard image generation unit generates an ultrasonic standard image about the acquired ultrasonic image data. A display unit(130) displays the ultrasonic standard image. [Reference numerals] (110) Image data acquisition unit; (120) Standard image generation unit; (130) Display unit
Participants will be sitting in a chair performing hand dexterity tasks in 0C (32F) conditions. Total rest period is 2 hours. After 2 hours, participants will perform athletic performance related tasks consisting of agility, power, muscular strength, and aerobic fitness.
The study included the screening period (no more than 28 days after the subject signed the informed consent form to the first medication), the treatment period (until the investigator assessed that there was no clinical benefit, intolerable toxicity or withdrew the informed consent, whichever occurred first) and the follow-up period (including safety follow-up, disease progress follow-up and survival follow-up). Subjects will be screened and evaluated within 28 days before the first medication to determine whether they meet the study conditions. During the screening period, tumor samples of the subjects need to be collected. Subjects who meet the study conditions will be treated according to the study medication plan until the following conditions occur: the investigator judges that the subject cannot continue to benefit, there is intolerable toxicity, there is a concomitant disease that affects further treatment, the investigator decides, the subject withdraws his informed consent or the treatment needs to be terminated for other reasons specified in the plan (whichever occurs first). The investigator regularly evaluated the tumor response of all subjects according to RECIST 1.1 standard. Subjects were evaluated once every 6 weeks (± 7 days) within 54 weeks after enrollment, and then once every 9 weeks (± 7 days). For subjects undergoing treatment, their clinical decisions are based on the tumor response evaluated by the researchers
Patients with Chronic Kidney Disease (CKD) have been shown to have high coronary calcium scores (CAC), but the temporal association between Glomerular Filtration Rate, CVD risk factors and CAC has not been described. This is a single-center, longitudinal, observational study. Subjects included adults aged 18 years to 65 years old without preexisting coronary artery disease (CAD). The CKD subjects (GFR \< 60 ml/min) were recruited from the Nephrology Clinic, and the control subjects (GFR \>/=60ml/min) were recruited from the Internal Medicine Clinic. Laboratory measurements and MDCT scan were performed at baseline and after 12 months. Baseline CAC and average intact parathyroid hormone (iPTH) level were significantly greater in the CKD group. Baseline CAC scores of the CKD group were twice the value of the control group; however, CAC scores over one year were unchanged from baseline. These observations suggest that CAC begins in earlier stages of CKD. Moreover, novel CVD risk factors including iPTH may accelerate CAD progression in CKD.
A process for making foamed glasses and ceramics from sol-gels is disclosed. The method includes preparing a mixture of reactants capable of forming a sol-gel with addition of a catalyst to control the condensation stage followed by foaming using vigorous agitation in the presence of surfactants. The gelled bodies are aged, dried, and thermally stabilized to obtain a consolidated macroporous material. The resulting structure comprises a three-dimensional network of spherical open pores that are thoroughly interconnected. The process may involve sol-gel systems using a mixture of metal alkoxides, and may produce glasses in unary systems (SiO2), binary systems (70% mol SiO2-30% mol CaO), and ternary systems (60% mol SiO2, 36% mol CaO, 4% mol P2O5). The macroporous material has pores in the 10-500 µm range and has potential for use as matrix in tissue engineering, in bone repair, and in organ regeneration.
The invention discloses LincRNA application in the medicine of preparation regulation and control methotrexate oncotherapy drug resistance, the coded sequence of described lincRNA such as SEQ? ID? shown in No.1. Non-coding RNA? H19(its sequence such as SEQ? ID? shown in No.1) compete son as a miRNA sponge or miRNA, can be combined with some miRNAs, these miRNAs can be combined with ABCC2/ABCG2 gene 3 '-UTR, thus suppressing ABCC2/ABCG2 gene expression, and then improve methotrexate toleration in tumor cell; Non-coding RNA? H19 is possible as a methotrexate diagnostic markers in oncotherapy or molecular target, to improve the effect of oncotherapy.
The investigators conducted a randomized controlled trial to study the feasibility and efficacy of an SBIRT programme for hazardous drinkers presenting in an ED. All patients older than 18 years old attending the emergency department were potentially eligible. Cognitively impaired or medically unstable patients were excluded. Patients seeking treatment for alcohol use were also excluded. Patients were randomized to two groups, with the control group receiving two leaflets - one regarding alcohol use, and the other giving information about the study protocol. The intervention group received the same leaflets as well as a brief motivational intervention on alcohol use; and, where appropriate, a referral to specialised treatment. The primary outcomes were the proportion of hazardous drinkers measured by AUDIT-C scale and the proportion of patients attending specialised treatment at 1.5 and 4.5 months and 1 year.
The recommended dose of SUPPRELIN LA is one implant every 12 months. Each implant contains 50 mg histrelin acetate. The implant is inserted subcutaneously in the inner aspect of the upper arm and provides continuous release of histrelin acetate (65 mcg/day) for 12 months of hormonal therapy. SUPPRELIN LA should be removed after 12 months of therapy (the implant has been designed to allow for a few additional weeks of histrelin acetate release, in order to allow flexibility of medical appointments). At the time an implant is removed, another implant may be inserted to continue therapy. Discontinuation of SUPPRELIN LA should be considered at the discretion of the physician and at the appropriate time point for the onset of puberty (approximately 11 years for females and 12 years for males).
To achieve maximum contraceptive effectiveness,Desogestrel and Ethinyl Estradiol Tablets, USP and Ethinyl Estradiol Tablets, USP must be taken exactly as directed and at intervals not exceeding 24 hours. Desogestrel and Ethinyl Estradiol Tablets, USP and Ethinyl Estradiol Tablets, USP may be initiated using either a Sunday start or a Day 1 start.

NOTE: Each cycle pack dispenser is preprinted with the days of the week, starting with Sunday, to facilitate a Sunday start regimen. Six different “day label strips” are provided with each cycle pack dispenser in order to accommodate a Day 1 start regimen. In this case, the patient should place the self-adhesive “day label strip” that corresponds to her starting day over the preprinted days.

IMPORTANT: The possibility of ovulation and conception prior to initiation of use of Desogestrel and Ethinyl Estradiol Tablets, USP and Ethinyl Estradiol Tablets, USP should be considered.

The use of Desogestrel and Ethinyl Estradiol Tablets, USP and Ethinyl Estradiol Tablets, USP for contraception may be initiated 4 weeks postpartum in women who elect not to breastfeed. When the tablets are administered during the postpartum period, the increased risk of thromboembolic disease associated with the postpartum period must be considered (see CONTRAINDICATIONS and WARNINGS concerning thromboembolic disease. See also PRECAUTIONS for Nursing mothers). 

If the patient starts on Desogestrel and Ethinyl Estradiol Tablets, USP and Ethinyl Estradiol Tablets, USP postpartum, and has not yet had a period, she should be instructed to use another method of contraception until a white tablet has been taken daily for 7 days.
BACKGROUND: Teleaudiology can potentially improve access to hearing healthcare services. Remote hearing aid fittings offer a new mode of service delivery that removes barriers of geography and access to an audiologist. Real-ear measurements (REMs) are the gold standard for hearing aid output verification but require in-clinic appointments. This study will investigate whether remote hearing aid fittings can provide clinically equivalent outcomes when compared to current, in-clinic, best practice guidelines.
RESEARCH DESIGN: A repeated measure, double-blinded crossover design will be used. Participants will be randomly allocated to one of two groups to determine order of intervention, balanced for degree of hearing loss.
STUDY SAMPLE: Sixty adults with mild to moderate hearing loss and at least 1 year of experience with hearing aids will be recruited.
DATA COLLECTION AND ANALYSIS: Participants will complete two hearing aid fitting protocols, one using an in-clinic fitting process and the other using a remote (at-home) fitting process. In-clinic fittings will include REMs with adjustments to standard (NAL-NL2) prescription targets. The two fitting protocols will then be randomly assigned to participants in a crossover design, so participants and researchers will be blinded to the order of the two fitting protocols. Participants will then have a 4-week period with follow-up appointments for participant-directed gain adjustment. For each fitting protocol, participants will complete objective measurements of final hearing aid output with REMs, speech-in-noise testing, subjective measurements of hearing aid performance, and quality of life measurements. They will then begin an identical period of living with, adjusting, and objective assessment with the other fitting protocol. Data will be analysed as repeated measures with statistical control for potential confounding variables.
RESULTS: Data will compare the four-frequency average real-ear aided response (4FREAR) for hearing aids programmed in-clinic and hearing aids programmed remotely, after participant-directed gain adjustments. Secondary measures will assess clinically significant differences in estimated speech intelligibility, hearing-related quality of life, hearing aid benefit, sound quality and preference, and speech-in-noise ability.
CONCLUSIONS: This study will inform the development of best practice guidelines for remote hearing aid fittings. If no clinically significant differences are found between in-clinic and remote fit hearing aids, it has the potential to expand teleaudiology initiatives.
TRIAL REGISTRATION: Australian New Zealand Clinical Trial Registry, ACTRN12623000028606p . Date of registration: 12 January 2023.
The 2.0g SRT2104 treatment group will be administered 8 SRT2104 capsules per day. 2.0g SRT2104 will be administered orally once daily for twenty-eight consecutive days. Dosing will take place at approximately the same time every day, approximately 15 minutes following the consumption of a standardized meal, and subjects must wait at least 1-2hrs after dosing before consuming additional calories. Water is permitted ad libitum.
Rural-dwelling adults will be interviewed to map their social network structure, determine the types of social support provided by members of their social network, and identify key players within these networks. A subset of participants (\~4) will be identified as Community Health Workers and will receive training with the Diabetes Empowerment Education Program (DEEP).
Participants will be provided with pre-weighed, foil sachets containing a ready-to-mix flavoured powdered supplement that is rich in milk fat globule membrane (and associated complex milk lipids). They will be asked to consume two sachets daily (mixed with water) during the 4-week study period. Sachets will be coded to maintain study blinding.